Med. praxi. 2025;22(3):176-180 | DOI: 10.36290/med.2025.027

Myths and facts about antisecretory therapy

MUDr. Tomáš Skutil, doc. MUDr. Radek Kroupa, Ph.D., doc. MUDr. Jiří Dolina, Ph.D.
Interní gastroenterologická klinika, Fakultní nemocnice Brno

Antisecretory therapy, including proton pump inhibitors and H2-blockers, plays a key role in the treatment of gastroesophageal reflux disease and other upper gastrointestinal diseases. Although this therapy is widely used, there are many misconceptions that can influence the decision-making of primary care physicians. This article aims to shed light on the myths and facts regarding antisecretory therapy, provide practical information for physicians, and promote a rational approach to its use.

Keywords: antisecretory therapy, proton pump inhibitors, H2-blockers, esophageal reflux disease, adverse effects, drug interactions.

Received: March 13, 2025; Revised: April 8, 2025; Accepted: April 10, 2025; Published: June 26, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Skutil T, Kroupa R, Dolina J. Myths and facts about antisecretory therapy. Med. praxi. 2025;22(3):176-180. doi: 10.36290/med.2025.027.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 26.6.2026

    References

    1. Katz PO, Dunbar KB, Schnoll­‑Sussman FH, et al. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022 Jan 1;117(1):27-56. Go to original source... Go to PubMed...
    2. Nugent CC, Falkson SR, Terrell JM. H2 Blockers. StatPearls [Internet]. 2025 Jan, [cited 2025 Jan]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK525994/.
    3. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008 Dec;10(6):528-34. Go to original source... Go to PubMed...
    4. Shinozaki S, Osawa H, Hayashi Y, et al. Long­‑term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor­‑resistant gastroesophageal reflux disease. Biomed Rep. 2021 Mar;14(3):32. doi: 10.3892/br.2021.1408. Epub 2021 Feb 1. PMID: 33585034; PMCID: PMC7873583. Go to original source... Go to PubMed...
    5. Skutil T, Konečný Š, Vaculová J. Refluxní choroba jícnu - současný pohled. ACTA MEDICINAE Vnitřní lékařství. 2023;14.
    6. Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on De­‑Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology. Apr;162(4) 2022:1334-1342. Go to original source... Go to PubMed...
    7. Raghu G, Remy­‑Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47. doi: 10.1164/rccm.202202-0399ST. Go to original source... Go to PubMed...
    8. Kroupa R, Skutil T, Dolina J. Racionalizace terapie nemocí horní části trávicího traktu (nejen) v geriatrii. Geriatrie a Gerontologie. 2024;13(3):144-149.
    9. Muheim L, Signorell A, Markun S, et al. Potentially inappropriate proton­‑pump inhibitor prescription in the general population: a claims­‑based retrospective time trend analysis. Therapeutic Advances in Gastroenterology. 2021;14. Go to original source... Go to PubMed...
    10. Thurber KM, Otto AO, Stricker SL. Proton pump inhibitors: Understanding the associated risks and benefits of long­‑term use. Am J Health Syst Pharm. 2023 Apr 8;80(8):487-494. Go to original source... Go to PubMed...
    11. Dunbar KB, Souza RF, Spechler SJ. The Effect of Proton Pump Inhibitors on Barrett's Esophagus. Gastroenterol Clin North Am. 2015 Jun;44(2):415-24. Go to original source... Go to PubMed...
    12. Lucendo AJ, Molina­‑Infante J, Arias Á, et al. Guidelines on eosinophilic esophagitis: evidence­‑based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017 Apr;5(3):335-358. Go to original source... Go to PubMed...
    13. Rossi A, Perrella L, Scotti S, et al. Approaches to Deprescribing Proton Pump Inhibitors in Clinical Practice: A Systematic Review. Journal of Clinical Medicine. 2024;13(20):6283. Go to original source... Go to PubMed...
    14. Kroupa R, Cyrany J, Dolina J, et al. Příznaky a onemocnění horní části trávicího traktu. Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře. Gastroenterologie. 2024; Praha. ISBN 978-80-88280-67-5.
    15. Begg M, Tarhuni M, N Fotso M, et al. Comparing the Safety and Efficacy of Proton Pump Inhibitors and Histamine-2 Receptor Antagonists in the Management of Patients With Peptic Ulcer Disease: A Systematic Review. Cureus. 2023 Aug 29;15(8):e44341. doi: 10.7759/cureus.44341. Go to original source... Go to PubMed...
    16. Kumar SS, Arvind S, Umpierrez AP. Things We Do for No Reason™: Routine use of proton pump inhibitors for peptic ulcer prophylaxis in adults on high­‑dose corticosteroids. J Hosp Med. 2023 Jul;18(7):630-632. doi: 10.1002/jhm.13095. Epub 2023 Apr 4. PMID: 37013890. Go to original source... Go to PubMed...
    17. Lechien JR, Saussez S, Karkos PD. Effects of acids, pepsin, bile acids, and trypsin on laryngopharyngeal reflux diseases: physiopathology and therapeutic targets. European Archives of Oto­‑Rhino­‑Laryngology. 2018;26:392-402.
    18. Tan CM, Juurlink DN. Navigating Drug Interactions with Proton Pump Inhibitors. JAMA Netw Open. 2024;7(7):e2419818. Go to original source... Go to PubMed...
    19. Deodhar M, Al Rihani SB, Arwood MJ, et al. Mechanisms of CYP450 Inhibition: Understanding Drug­‑Drug Interactions Due to Mechanism­‑Based Inhibition in Clinical Practice. Pharmaceutics. 2020;12(9):846. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.